Biomea Fusion, Inc. financial data

Symbol
BMEA on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 Middlefield Road, 4 Th Floor, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 427 % -55.7%
Debt-to-equity 35 % +115%
Return On Equity -151 % -118%
Return On Assets -112 % -87.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.6M shares +4.69%
Common Stock, Shares, Outstanding 36.3M shares +1.24%
Entity Public Float 124M USD -79.2%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 36.3M shares +1.43%
Weighted Average Number of Shares Outstanding, Diluted 36.3M shares +1.43%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 118M USD +15.2%
General and Administrative Expense 26M USD +10.2%
Operating Income (Loss) -144M USD -14.2%
Net Income (Loss) Attributable to Parent -138M USD -18.1%
Earnings Per Share, Basic -3.84 USD/shares -11%
Earnings Per Share, Diluted -3.84 USD/shares -11%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 58.3M USD -67%
Assets, Current 68.3M USD -61.9%
Property, Plant and Equipment, Net 3.77M USD -27%
Operating Lease, Right-of-Use Asset 6.85M USD -29.5%
Other Assets, Noncurrent 619K USD -88.8%
Assets 79.9M USD -60%
Accounts Payable, Current 12.9M USD +88.8%
Employee-related Liabilities, Current 452K USD -92.4%
Liabilities, Current 21.7M USD -5.19%
Operating Lease, Liability, Noncurrent 6.69M USD -14.5%
Liabilities 28.4M USD -7.58%
Retained Earnings (Accumulated Deficit) -387M USD -55.6%
Stockholders' Equity Attributable to Parent 51.6M USD -69.5%
Liabilities and Equity 79.9M USD -60%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -32M USD -33.2%
Net Cash Provided by (Used in) Financing Activities 116K USD -42.3%
Net Cash Provided by (Used in) Investing Activities -35K USD +98%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 36.3M shares +1.24%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -31.9M USD -24.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 58.6M USD -66.9%
Deferred Tax Assets, Valuation Allowance 114M USD +59.2%
Deferred Tax Assets, Gross 116M USD +55.5%
Operating Lease, Liability 8.77M USD -14.8%
Depreciation 1.75M USD +15.4%
Payments to Acquire Property, Plant, and Equipment 35K USD -98.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -138M USD -18.1%
Lessee, Operating Lease, Liability, to be Paid 12.2M USD -23.6%
Property, Plant and Equipment, Gross 7.95M USD +4.68%
Operating Lease, Liability, Current 2.08M USD -15.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.53M USD -44.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.9M USD -28.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +9.17%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.4M USD -24.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.44M USD +4.57%
Deferred Tax Assets, Operating Loss Carryforwards 48.9M USD +55.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.91M USD +76.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.47M USD +3.01%
Operating Lease, Payments 2.27M USD +66%
Additional Paid in Capital 439M USD +4.97%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.04M USD -32.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%